CA2400021A1 - Acides aryloxyacetiques utilises en cas de diabete et de troubles lipidiques - Google Patents
Acides aryloxyacetiques utilises en cas de diabete et de troubles lipidiques Download PDFInfo
- Publication number
- CA2400021A1 CA2400021A1 CA002400021A CA2400021A CA2400021A1 CA 2400021 A1 CA2400021 A1 CA 2400021A1 CA 002400021 A CA002400021 A CA 002400021A CA 2400021 A CA2400021 A CA 2400021A CA 2400021 A1 CA2400021 A1 CA 2400021A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- group
- alkenyl
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne une classe d'acides aryloxyacétiques, comprenant des composés qui sont de puissants agonistes du récepteur alpha et/ou gamma activé par les proliférateurs de peroxysomes (PPAR) et sont, par conséquent, utilisés dans le traitement, le contrôle ou la prévention du diabète non insulino-dépendant (DNID), de l'hyperglycémie, de la dyslipidémie, de l'hyperlipidémie, de l'hypercholestérolémie, de l'hypertriglycéridémie, de l'athérosclérose, de l'obésité, de la resténose vasculaire, de l'inflammation et d'autres maladies, troubles et pathologies induits par récepteur alpha et/ou gamma activé par les proliférateurs de peroxysomes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18359300P | 2000-02-18 | 2000-02-18 | |
US60/183,593 | 2000-02-18 | ||
PCT/US2001/004636 WO2001060807A1 (fr) | 2000-02-18 | 2001-02-14 | Acides aryloxyacetiques utilises en cas de diabete et de troubles lipidiques |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2400021A1 true CA2400021A1 (fr) | 2001-08-23 |
Family
ID=22673475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002400021A Abandoned CA2400021A1 (fr) | 2000-02-18 | 2001-02-14 | Acides aryloxyacetiques utilises en cas de diabete et de troubles lipidiques |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1259494A4 (fr) |
JP (1) | JP2003523336A (fr) |
AU (1) | AU784722B2 (fr) |
CA (1) | CA2400021A1 (fr) |
CO (1) | CO5261629A1 (fr) |
PE (1) | PE20011056A1 (fr) |
WO (1) | WO2001060807A1 (fr) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
CA2437118A1 (fr) * | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | Acides 2-aryloxy-2-arylalcanoiques utilises pour le traitement du diabetes et des troubles lipidiques |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
PT1427423E (pt) | 2001-09-08 | 2007-03-30 | Astrazeneca Ab | Derivados de benzotiazepina e benzotiadiazepina com actividade inibidora do transporte ileal de ácidos biliáres (ibat) para o tratamento de hiperlipidemia |
CN1585638A (zh) | 2001-09-14 | 2005-02-23 | 图拉里克公司 | 被连接的联芳基化合物 |
CA2467165A1 (fr) * | 2001-11-21 | 2003-06-05 | Merck & Co., Inc. | Composes therapeutiques pour le traitement d'etats dyslipidemiques |
AU2003207432A1 (en) | 2002-02-05 | 2003-09-02 | Eli Lilly And Company | Urea linker derivatives for use as ppar modulators |
WO2003075911A1 (fr) * | 2002-03-11 | 2003-09-18 | Peter Zahradka | Utilisation d'agonistes de ppar alpha dans le traitement de maladies vasculaires et renales |
WO2003088962A1 (fr) * | 2002-04-16 | 2003-10-30 | Merck & Co., Inc. | Therapie combinatoire faisant appel a un agoniste de ppar alpha/gamma |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
WO2004017967A1 (fr) * | 2002-08-22 | 2004-03-04 | Cornell Research Foundation, Inc. | Inhibiteurs de cox-2 multifonctionnels |
AU2003279981A1 (en) * | 2002-10-21 | 2004-05-13 | Janssen Pharmaceutica, N.V. | Treating syndrome x with substituted tetralins and indanes |
MXPA05004192A (es) * | 2002-10-21 | 2005-09-20 | Johnson & Johnson | Tetralinas e indanos sustituidos. |
RS20050318A (en) * | 2002-10-21 | 2007-09-21 | Janssen Pharmaceutica N.V., | Substituted tetralins and indanes |
BR0317028A (pt) * | 2002-12-10 | 2005-10-25 | Novartis Ag | Combinação de um inibidor de dpp-iv e um composto de ppar-alfa |
US8293751B2 (en) | 2003-01-14 | 2012-10-23 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
JP2006516280A (ja) | 2003-01-20 | 2006-06-29 | ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー | 血漿コレステロール及びトリアシルグリセロールレベルを減少するためにスフィンゴ脂質を使用する方法 |
NL1022443C2 (nl) | 2003-01-20 | 2004-07-22 | Tno | Sphingolipiden voor verbetering van de samenstelling van de darmflora. |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
EP1457206A1 (fr) * | 2003-03-13 | 2004-09-15 | Fournier Laboratories Ireland Limited | Utilisation combinée d'un fibrate et de l'orlistat pour le traitement de l'obésité |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
SE0301009D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
AU2004257267B2 (en) | 2003-07-14 | 2009-12-03 | Arena Pharmaceuticals,Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
EP1576894A1 (fr) * | 2004-03-16 | 2005-09-21 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Utilisation de sphingolipides pour la prevention et le traitement diabete deType 2, la resistance a l'insuline et syndrome metabolique |
EP1729597B1 (fr) * | 2004-03-16 | 2011-03-09 | Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO | Utilisation de sphingolipides pour la prevention et le traitement diabete de type 2, la resistance a l'insuline et syndrome metabolique |
ES2352085T3 (es) | 2004-05-05 | 2011-02-15 | High Point Pharmaceuticals, Llc | Nuevos compuestos, su preparación y uso. |
US8053598B2 (en) | 2004-05-05 | 2011-11-08 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
ATE488236T1 (de) * | 2004-09-16 | 2010-12-15 | Merck Sharp & Dohme | Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen |
US7601847B2 (en) | 2004-10-26 | 2009-10-13 | Wyeth | Preparation and purification of 4-(indazol-3-yl)phenols |
WO2006056752A1 (fr) | 2004-11-23 | 2006-06-01 | Astrazeneca Ab | Derives d'acide phenoxyacetique utiles pour le traitement des maladies respiratoires |
ATE539741T1 (de) | 2004-11-30 | 2012-01-15 | Tno | Sphingolipide bei der behandlung und prävention von hepatischer steatose |
WO2006059744A1 (fr) * | 2004-11-30 | 2006-06-08 | Nippon Chemiphar Co., Ltd. | ACTIVANT DE RÉCEPTEUR δ ACTIVÉ PAR UN PROLIFÉRATEUR DE PEROXISOME |
CN101128441A (zh) | 2005-03-04 | 2008-02-20 | 默克公司 | 具有抗糖尿病活性的稠合芳香化合物 |
WO2006123182A2 (fr) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Sulfones de cyclohexyle pour le traitement du cancer |
ES2449618T3 (es) | 2005-06-30 | 2014-03-20 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de PPAR-delta |
FR2890071B1 (fr) | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
FR2890072A1 (fr) | 2005-09-01 | 2007-03-02 | Fournier S A Sa Lab | Nouveaux composesde pyrrolopyridine |
TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
JP5155171B2 (ja) | 2005-10-06 | 2013-02-27 | アストラゼネカ・アクチエボラーグ | 新規化合物 |
EA015717B1 (ru) | 2005-12-22 | 2011-10-31 | ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Феноксиуксусные кислоты в качестве активаторов ppar дельта |
CA2645719A1 (fr) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Nouveaux composes, leur preparation et utilisation |
WO2008137105A1 (fr) | 2007-05-07 | 2008-11-13 | Merck & Co., Inc. | Procédé de traitement à l'aide de composés aromatiques fusionnés ayant une activité anti-diabétique |
UA100983C2 (ru) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
US7919509B2 (en) | 2008-02-29 | 2011-04-05 | Kowa Company, Ltd. | 2-oxochromene derivatives |
JP2013006769A (ja) * | 2009-10-08 | 2013-01-10 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤活性化受容体の活性化剤 |
KR101871011B1 (ko) | 2010-09-22 | 2018-06-25 | 아레나 파마슈티칼스, 인크. | Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료 |
EP3777864A1 (fr) | 2010-11-08 | 2021-02-17 | Albireo AB | Inhibiteurs ibat pour le traitement de maladies du foie |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
EP3043789B1 (fr) | 2013-09-09 | 2020-07-08 | vTv Therapeutics LLC | Utilisation des agonistes de ppar-delta pour le traitement de l'atrophie musculaire |
CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
EP3012252A1 (fr) | 2014-10-24 | 2016-04-27 | Ferring BV | Formes crystallines d'Elobixibat |
UA126268C2 (uk) | 2015-01-06 | 2022-09-14 | Арена Фармасьютікалз, Інк. | СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub> |
EA201890096A1 (ru) | 2015-06-22 | 2018-08-31 | Арена Фармасьютикалз, Инк. | КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
JP2020530448A (ja) | 2017-08-09 | 2020-10-22 | アルビレオ・アクチボラグ | コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用 |
CN112449637B (zh) | 2018-06-05 | 2024-03-19 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
EP3810581A1 (fr) | 2018-06-20 | 2021-04-28 | Albireo AB | Modifications cristallines d'odévixibat |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
JP2023504644A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
PE20230234A1 (es) | 2019-12-04 | 2023-02-07 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
JP2023504643A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
CA3158276A1 (fr) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Composes de benzothia(di)azepine et leur utilisation en tant que modulateurs d'acide biliaire |
CN111793066B (zh) * | 2020-07-17 | 2022-04-08 | 瀚海新拓(杭州)生物医药有限公司 | 苯并五元杂环磺酰胺类化合物、其制备方法、药物组合物及应用 |
JP2023537285A (ja) | 2020-08-03 | 2023-08-31 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
CA3196488A1 (fr) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat pour le traitement de la cholestase intrahepatique familiale progressive (cifp) |
KR20230117393A (ko) | 2020-12-04 | 2023-08-08 | 알비레오 에이비 | 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의용도 |
WO2023147309A1 (fr) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Utilisation d'agonistes ppar-delta dans le traitement d'une maladie |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4728662A (en) * | 1977-11-21 | 1988-03-01 | Hoechst-Roussel Pharmaceuticals Inc. | 1,2-benzisoxazoloxyacetic acids and related compounds |
US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
-
2001
- 2001-02-14 AU AU38214/01A patent/AU784722B2/en not_active Ceased
- 2001-02-14 CA CA002400021A patent/CA2400021A1/fr not_active Abandoned
- 2001-02-14 WO PCT/US2001/004636 patent/WO2001060807A1/fr active Application Filing
- 2001-02-14 JP JP2001560192A patent/JP2003523336A/ja not_active Withdrawn
- 2001-02-14 EP EP01910624A patent/EP1259494A4/fr not_active Withdrawn
- 2001-02-15 CO CO01011989A patent/CO5261629A1/es not_active Application Discontinuation
- 2001-02-16 PE PE2001000178A patent/PE20011056A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2003523336A (ja) | 2003-08-05 |
AU784722B2 (en) | 2006-06-01 |
AU3821401A (en) | 2001-08-27 |
EP1259494A1 (fr) | 2002-11-27 |
PE20011056A1 (es) | 2001-10-22 |
WO2001060807A1 (fr) | 2001-08-23 |
EP1259494A4 (fr) | 2004-09-15 |
CO5261629A1 (es) | 2003-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU784722B2 (en) | Aryloxyacetic acids for diabetes and lipid disorders | |
US6569879B2 (en) | Aryloxyacetic acids for diabetes and lipid disorders | |
US6645997B2 (en) | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | |
AU2001277056B2 (en) | N-substituted indoles useful in the treatment of diabetes | |
US7495020B2 (en) | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | |
US6713508B2 (en) | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | |
US7393960B2 (en) | Indoles having anti-diabetic activity | |
AU2001277056A1 (en) | N-substituted indoles useful in the treatment of diabetes | |
AU2002251978A1 (en) | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | |
EP1587535A2 (fr) | Derives de n-cyclohexylaminocarbonyl benzenesulfonamide | |
AU2001292874A1 (en) | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | |
US7297715B2 (en) | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | |
EP1796665A2 (fr) | Composes pour traitement de la dyslipidemie et autres troubles lipidiques | |
US20090069385A1 (en) | Antidiabetic Oxazolidinediones and Thiazolidinediones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |